Amgen’s Aranesp v. Procrit Promotional Claims Result In Off-Label Guilty Plea

Amgen pled guilty to marketing Aranesp off-label as part of a global settlement with the government; the final agreement, expected to be approved on Dec. 19, could involve marketing practices of Enbrel and six other drugs.

Amgen Inc.’s efforts to obtain a marketing edge for Aranesp (darbepoeitn alfa) over Johnson & Johnson’s Procrit (epoetin alfa) led to the company’s guilty plea for off-labeling marketing.

The U.S. Attorney’s Office for the Eastern District of New York announced on Dec. 18 that Amgen had pled guilty...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from United States

More from North America